ArticleHuman vaccines & immunotherapeutics2024
Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women.
Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.Human vaccines & immunotherapeutics · 2026Article
- Beyond the Usual Suspects: Emerging Associations Between Epstein-Barr Virus Infection/Infectious Mononucleosis and Cancers.Reviews in medical virology · 2026Review
- A Pocket Manual for Human Papillomavirus Vaccines.Vaccines · 2026Review
- Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income country.Journal of gynecologic oncology · 2026Article
- Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age.NPJ vaccines · 2026Article
- The Epidemiology of Human Papillomavirus (HPV) Infections in Poland in the Light of the Nationwide HPV Vaccination Program for Children Aged 12-13 and Updated HPV DNA Detection Guidelines.International journal of molecular sciences · 2026Article
- Perception and Acceptance of HPV Vaccination Among Women Treated for Cervical Intraepithelial Neoplasia: An Evidence-Based Narrative Review.Journal of clinical medicine · 2025Review
- HPV Vaccine: An Effective but Underutilized Prevention Tool.International journal of environmental research and public health · 2025Article
- The human papilloma virus (HPV) vaccination recommendations and funded programs for adults: A targeted literature review.Human vaccines & immunotherapeutics · 2025Review
- Global Perspectives on HPV Vaccination: Achievements, Challenges, and Lessons from the Brazilian Experience.Vaccines · 2025Review
- Immunogenicity comparison of anThe Lancet regional health. Western Pacific · 2025Article
- Long-term efficacy and immunopersistence of anThe Lancet regional health. Western Pacific · 2025Article
- Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- The incidence of high-risk HPV infections in Slovakia at the start of the national organized screening for cervical cancer.Infectious agents and cancer · 2025Article
- The Vaginal Microbiota, Human Papillomavirus, and Cervical Dysplasia-A Review.Medicina (Kaunas, Lithuania) · 2025Review
- Impact of HPV Catch-Up Vaccination on High-Grade Cervical Lesions (CIN2+) Among Women Aged 26-30 in Northern Norway.Vaccines · 2025Article
- Global burden of cancer in women, 1990-2021: a systematic analysis from the GBD 2021 study.Frontiers in oncology · 2025Article
- Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pivotal study in women aged 16-26 years demonstrated that the nine-valent human papillomavirus (9vHPV) vaccine was efficacious against high-grade cervical dysplasia related to the HPV types covered by the vaccine. To evaluate whether effectiveness remains above 90% for up to 14 years post-vaccination, a long-term follow-up (LTFU) extension of the study was conducted in Denmark, Norway, and Sweden (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.